IMTX

Immatics N.V. (IMTX) | Rumor.io

Immatics

IMTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,622

Bullish sentiment (50-day avg)38%

Price to earnings ratio26.8

Market capitalization1.3B

Earnings per share-1.81

Dividend yield (TTM)—

Revenue (annual)48.3M

Net income (annual)-196.4M

Social

What share of all stock conversation is about IMTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Dec 5

Immatics N.V. (IMTX) announces a $125 million underwritten offering of 12.5 million shares at $10 per share.
The offering is expected to close on December 8, 2025, and is likely to be dilutive, potentially triggering selling pressure.
Analysts have raised their target price for IMTX, with Leerink increasing its target to $17 from $16, and Rothschild Redburn initiating coverage with a Buy rating and a $263 target.

Generated by AI

Sentiment

Of the messages about IMTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.15% +12.08
Bearish	—	—	—	16.85% -12.08

Bullish· Dec 14

Immatics' TCER platform has shown promising potential, and the company's partnership with Bristol Myers Squibb for IMA401 is a significant deal with favorable terms.
The collaboration between Immatics and Bristol Myers Squibb has been hailed as a major catalyst for Immatics, with analysts increasing the price target to $32 and maintaining an Outperform rating.
Immatics' stock is expected to rise significantly, with some predicting a price of $15.00, and the company is seen as a potential takeover target due to its promising cancer treatment compounds.

Bearish· Mar 17

The company's data needs significant improvement to justify its current price movement.
The stock's recent price action may be due to price suppression by a large holder, with shares being held below a certain level.
The stock's price may be experiencing a slow bleed, with a downward trend that could continue if support levels are breached.

Generated by AI

Topics

Of the messages about IMTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.54%
Earnings	—	0%	0%	10.39%
Analysts	—	0%	0%	13.73%
Controversies	—	0%	0%	0.53%
Macro	—	0%	0%	1.41%
Technical Analysis	—	0%	0%	4.4%

Oct 10

Immatics N.V. ($IMTX) announces updated Phase 1b clinical data on ACTengine IMA203 TCR-T targeting PRAME in melanoma patients.
The company provides an update on its upcoming SUPRAME Phase 3 trial.
Immatics announces a proposed $150 million underwritten public offering of its ordinary shares, with Jefferies, BofA Securities, and Leerink Partners as joint book-running managers.

Generated by AI

Community

Of the messages about IMTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	42.86%	39%
Newcomers	—	0%	57.14%	61%

Regulars· Oct 10

Immatics' ACTengine IMA203 TCR-T therapy shows promising results in 2L melanoma patients, with a 50% overall response rate and a 1-year overall survival rate of 93%.
The company plans to initiate a Phase 3 trial, SUPRAME, based on the positive data from the Phase 1b study, and is raising $150 million through a public offering to fund the trial.
The therapy's efficacy appears to be superior to that of TIL therapy, with a significant advantage in the treatment of melanoma, according to the regulars.

Newcomers· Jun 20

Newcomers are comparing Immatics N.V. (IMTX) to another company, highlighting differences in their research and development processes.
Some are pointing out that Immatics N.V. has a more extensive track record of clinical trial success, with a 50% disease control rate, compared to another company's 13% rate.
The limited availability of Immatics N.V.'s treatment due to its customized nature is seen as a drawback by some newcomers.

Generated by AI

News

Why is Immatics stock climbing today?

1mo agoInvesting.com

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

1mo agoSeeking Alpha

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

1mo agoBenzinga

Immatics Announces $150 Million Underwritten Offering

Immatics (IMTX) said Tuesday that it has agreed to sell 12,945,916 ordinary shares at $8.69 each, an

1mo agoYahoo Finance

Immatics earnings on deck as analysts eye revenue trajectory

1mo agoInvesting.com

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeledCompany plans to proceed directly to a streamlined final analysis for the primary endpoint, PFS, while strengthening power for the secondary endpoint, OS, to enhance the commercial product profile SUP

1mo agoYahoo Finance

Also Discussed

Investors talking about IMTX also mention

#	Name	Attention
1	Immunocore Holdings plc ADRIMCR	0%0
2	Bicycle Therapeutics plc - ADRBCYC	0%0
3	ALPN - Alpine Immune Sciences, Inc.	——
4	iShares ESG Aware USD Corporate Bond ETFSUSC	0%0
5	Autolus Therapeutics plc ADRAUTL	0%+0
6	AFMD - Affimed N.V.	——
7	Fate Therapeutics Inc.FATE	0%new
8	U.S. Physical Therapy, Inc.USPH	0%0
9	Arcus Biosciences, Inc.RCUS	0%new
10	Cullinan Therapeutics Inc.CGEM	0%new

Immatics N.V.

Healthcare
Biotechnology

Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics. Its current work centers on PRAME-targeted immunotherapy, a cancer-associated target used across multiple oncology applications. Immatics N.V. operates as a research-driven oncology company with a pipeline built around precision immunotherapy platforms and collaborations that support the development of next-generation cancer treatments. Headquartered in Tübingen, Germany, the company serves the broader biopharmaceutical market through its focus on novel therapies for patients with difficult-to-treat cancers.

Website

Location

Paul-Ehrlich-Strasse 15

Tübingen, 72076

Germany

Social

What share of all stock conversation is about IMTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Dec 5

Immatics N.V. (IMTX) announces a $125 million underwritten offering of 12.5 million shares at $10 per share.
The offering is expected to close on December 8, 2025, and is likely to be dilutive, potentially triggering selling pressure.
Analysts have raised their target price for IMTX, with Leerink increasing its target to $17 from $16, and Rothschild Redburn initiating coverage with a Buy rating and a $263 target.

Generated by AI

Sentiment

Of the messages about IMTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.15% +12.08
Bearish	—	—	—	16.85% -12.08

Bullish· Dec 14

Immatics' TCER platform has shown promising potential, and the company's partnership with Bristol Myers Squibb for IMA401 is a significant deal with favorable terms.
The collaboration between Immatics and Bristol Myers Squibb has been hailed as a major catalyst for Immatics, with analysts increasing the price target to $32 and maintaining an Outperform rating.
Immatics' stock is expected to rise significantly, with some predicting a price of $15.00, and the company is seen as a potential takeover target due to its promising cancer treatment compounds.

Bearish· Mar 17

The company's data needs significant improvement to justify its current price movement.
The stock's recent price action may be due to price suppression by a large holder, with shares being held below a certain level.
The stock's price may be experiencing a slow bleed, with a downward trend that could continue if support levels are breached.

Generated by AI

Topics

Of the messages about IMTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	69.54%
Earnings	—	0%	0%	10.39%
Analysts	—	0%	0%	13.73%
Controversies	—	0%	0%	0.53%
Macro	—	0%	0%	1.41%
Technical Analysis	—	0%	0%	4.4%

Oct 10

Immatics N.V. ($IMTX) announces updated Phase 1b clinical data on ACTengine IMA203 TCR-T targeting PRAME in melanoma patients.
The company provides an update on its upcoming SUPRAME Phase 3 trial.
Immatics announces a proposed $150 million underwritten public offering of its ordinary shares, with Jefferies, BofA Securities, and Leerink Partners as joint book-running managers.

Generated by AI

Community

Of the messages about IMTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	42.86%	39%
Newcomers	—	0%	57.14%	61%

Regulars· Oct 10

Immatics' ACTengine IMA203 TCR-T therapy shows promising results in 2L melanoma patients, with a 50% overall response rate and a 1-year overall survival rate of 93%.
The company plans to initiate a Phase 3 trial, SUPRAME, based on the positive data from the Phase 1b study, and is raising $150 million through a public offering to fund the trial.
The therapy's efficacy appears to be superior to that of TIL therapy, with a significant advantage in the treatment of melanoma, according to the regulars.

Newcomers· Jun 20

Newcomers are comparing Immatics N.V. (IMTX) to another company, highlighting differences in their research and development processes.
Some are pointing out that Immatics N.V. has a more extensive track record of clinical trial success, with a 50% disease control rate, compared to another company's 13% rate.
The limited availability of Immatics N.V.'s treatment due to its customized nature is seen as a drawback by some newcomers.

Generated by AI

Immatics

Social

Dec 5

Bullish· Dec 14

Bearish· Mar 17

Oct 10

Regulars· Oct 10

Newcomers· Jun 20

Why is Immatics stock climbing today?

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Immatics Announces $150 Million Underwritten Offering

Immatics earnings on deck as analysts eye revenue trajectory

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Also Discussed

Immatics N.V.

Company Information

Location

Why is Immatics stock climbing today?

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

Immatics Announces $150 Million Underwritten Offering

Immatics earnings on deck as analysts eye revenue trajectory

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Also Discussed

Social

Dec 5

Bullish· Dec 14

Bearish· Mar 17

Oct 10

Regulars· Oct 10

Newcomers· Jun 20